medigraphic.com
Instituto Nacional de Neurología y Neurocirugía

2012, Number 2

<< Back Next >>

Arch Neurocien 2012; 17 (2)

Charcot-Marie-Tooth: present situation and prospects

Lara-Aguilar RA,Juárez-Vázquez CI, Juárez-Rendón KJ, Gutiérrez-Amavizca BE, Barros-Núñez P

Language: Spanish
References: 57
Page: 110-118
PDF size: 121.82 Kb.


ABSTRACT

The Charcot-Marie-Tooth disease is defined as a sensory-motor polineurophatic abnormality, of demyelinating or axonal type, and genetic and clinical heterogeneity. Objective: this review is intended to update the clinical spectrum of this disease, as well as to know the molecular and therapeutic advances that contribute to understand and manage better this heterogeneous entity. Development: the Charcot-Marie-Tooth disease is a genetically complex syndrome with more than 30 associated genes; it is one of the more common hereditary neuropathies, whose reports indicate an estimated prevalence of 17-25 cases / 100,000 inhabitants. The clinical spectrum is broad, without an established genotype-phenotype correlation; however, there are a number of clinical features that allow their inclusion in several clinical subtypes. Typically, the patients present with distal muscle weakness and atrophy often associated with foot sensory loss and mild to moderate depression of tendon reflexes. Conclusions: the Charcot-Marie-Tooth classification is complex and constantly subject to a review of new genes and mutations. The observed clinical variability coincides with the involvement of different genes and proteins that help maintain function and integrity of the peripheral nerve, so that they become an important research target for developing new and better therapies.


REFERENCES

  1. Online Mendelian Inheritance in Man (OMIM). URL http:// www.ncbi.nlm.nih.gov/omim [11.11.2011].

  2. Guðmundsson B, Ólafsson E, Jakobsson F, Lúðvígsson P. Prevalence of symptomatic Charcot-Marie-Tooth disease in iceland: a study of a well-defined population. Neuroepidemiology 2010;34:13-7.

  3. Palau F, Cuesta A, Pedrola L. Avances en la genética molecular de las neuropatías hereditarias. Rev Neurol 2002;35:246-53.

  4. Saporta A, Sottile S, Miller L, Feely S, Siskind C, Shy M. Charcot- Marie-Tooth disease subtypes and genetic testing strategies. Ann Neurol 2011;69:22-33.

  5. Szigeti K, Lupski J. Charcot-Marie-Tooth disease. Eur J Hum Genet 2009; 17: 703-10.

  6. Ismailov SM, Fedotov VP, Dadali L, Polyakov AV, Van Broeckhoven C, Ivanov VI et al. A new locus for autosomal dominant Charcot-Marie-Tooth type 2 (CMT2F) maps to chromosome 7q11-q21. Eur J of Hum Genet 2001; 9: 646-50.

  7. Sevilla T, Vilchez J. Diferentes fenotipos del síndrome de Charcot-Marie-Tooth causados por mutaciones del mismo gen: ¿siguen siendo útiles los criterios de clasificación clásicos?. Neurología 2004;19:264-71.

  8. Herman M, Delmis J, Ivaniseviv M, Zupic T. Pregnancies and deliveries in patients with Charcot-Marie-Tooth disease. Acta Med Croatica 2010; 64 (3): 215-20.

  9. Colomer-Oferil J. Aspectos clínicos y abordaje diagnóstico y terapéutico de las neuropatías hereditarias sensitivomotoras. Rev Neurol 2002; 35: 239-45.

  10. Thaxton C, Bhat MA. Myelination and regional domain differentiation of the axon. Results Probl Cell Differ 2009;48: 1-28.

  11. Kamholz J, Menichella D, Jani A, James G, Lewis RA, Krajewski KM, et al. Charcot-Marie-Tooth disease type 1: molecular pathogenesis to gene therapy. Brain 2000; 123: 222-33.

  12. Siegel GJ, Agranoff BW, Albers RW, et al. Basic neurochemistry: molecular, cellular and medical aspects. 6th edition. Editors. Philadelphia: Lippincott-Raven; 1999.

  13. Maier M, Berger P, Suter U. Understanding Schwann cell– neurone interactions: the key to Charcot–Marie–Tooth disease? J Anat 2002; 200: 357-66.

  14. Dezawa M. The interaction and adhesive mechanisms between axon and Schwann cell during central and peripheral nerve regeneration. Kaibogaku Zasshi 2000; 75(3): 255-65.

  15. Banchs I, Casasnovas C, Albertí A, De Jorge L, Povedano M, Montero J, et al. Diagnosis of Charcot-Marie-Tooth disease. J Biomedicine and Biotechnology 2009; 2009:985415.

  16. Dyck PJ. Inherited neuronal degeneration and atrophy affecting peripheral motor, sensory, and autonomic neurons. En: Dyck PJ, Thomas PK, Lambert EH, editors. Peripheral neuropathy. Philadelphia: Elsevier Saunders; 1975; 825-67.

  17. Szigeti K, Garcia CA, Lupski JR. Charcot-Marie-Tooth disease and related hereditary polyneuropathies: molecular diagnostics determine aspects of medical management. Genet Med 2006; 8(2):86-92.

  18. Shy ME. Charcot-Marie-Tooth disease: an update. Current Opinion in Neurology 2004; 17: 579-85.

  19. Verhamme C, van Schaik IN, Koelman JH, de Haan RJ, de Visser M. The natural history of Charcot–Marie-Tooth type 1A in adults: a 5-year follow-up study. Brain 2009; 132: 3252-62.

  20. Saifi GM, Szigeti K, Snipes GJ, Garcia CA, Lupski JR. Molecular mechanisms, diagnosis, and rational approaches to management of and therapy for Charcot-Marie-Tooth disease and related peripheral neuropathies. J Investig Med 2003; 51: 261-83.

  21. Gemignani F, Marbini. Charcot-Marie-Tooth disease (CMT): distinctive phenotypic and genotypic features in CMT type 2. J Neurol Sci 2001; 184:1-9.

  22. Nicholson G, Myers S. Intermediate forms of Charcot-Marie- Tooth neuropathy: a review. Neuromolecular Med 2006; 8:123-30.

  23. Bertorini T, Narayanaswami P, Rashed H. Charcot-Marie-Tooth Disease (Hereditar y Motor Sensor y Neuropathies) and Hereditary Sensory and Autonomic Neuropathies. Neurologist 2004; 10: 327-37.

  24. Chow CY, Zhang Y, Dowling JJ, Jin N, Adamska M, Shiga K. Mutation of FIG4 causes neurodegeneration in the pale tremor mouse and patients with CMT4J. Nature 2007;5; 448 (7149): 68-72.

  25. Huttner IG, Kennerson ML, Reddel SW, Radovanovic D, Nicholson GA. Proof of genetic heterogeneity in X-linked Charcot-Marie-Tooth disease. Neurol 2006;67:2016-21.

  26. Lee JH, Choi BO. Charcot-Marie-Tooth disease: Seventeen Causative Genes. J Clin Neurol 2006; 2(2): 92-106.

  27. Berciano J, Sevilla T, Casasnovas C, Sivera R, Vilchez JJ, Infante J et al. Guía diagnóstica en el paciente con enfermedad de Charcot-Marie-Tooth. Neurología. 2011. doi: 10.1016/ j.nrl.2011.04.015

  28. Patzkó A, Shy ME. Update on Charcot-Marie-Tooth disease. Curr Neurol Neurosci Rep 2011;11 (1):78-88.

  29. Hernández E, Arenas M. El diagnóstico de las neuropatías periféricas hereditarias y la genética molecular. Acta Ortop Mex 2008; 22: 268-77.

  30. Villegas H, Solís L, Martínez F, Escobar R, García B. Neuropatías periféricas hereditarias: Charcot-Marie-Tooth tipos 1 y 2. Cir Cir 2004;72:387-94.

  31. Milani M, Morbin M, Moggio M, Ripolone M, Jann S, Scaioli V, et al. Rapid progression of late onset axonal Charcot-Marie- Tooth disease associated with a novel MPZ mutation in the extracellular domain. J Neurol Neurosurg Psychiatry 2007;78:1263-6.

  32. Mandich P, Fossa P, Capponi S, Geroldi A, Acquaviva M, Gulli R, et al. Clinical features and molecular modelling of novel MPZ mutations in demyelinating and axonal neuropathies. Eur J Hum Genet 2009;17: 1129-34.

  33. Braathen G, Sand J, Lobato A, Høyer H, Russell M. MFN2 point mutations occur in 3.4% of Charcot-Marie-Tooth families. An investigation of 232 Norwegian CMT families. BMC Med Genet 2010; 11:48.

  34. Andrigo C, Boito C, Prandini P, Mostacciuolo M, Siciliano G, Angelini C, et al. A novel out-of-frame mutation in the neurofilament light chain gene (NEFL) does not result in Charcot-Marie-Tooth disease type 2E. Neurogenetics 2005;6:49-50.

  35. Kabzinska D, Perez-Olle R, Goryunov D, Drac H, Ryniewicz B, Hausmanowa- Petrusewicz I, et al. Is a novel I214M substitution in the NEFL gene a cause of Charcot-Marie-Tooth disease? Functional analysis using cell culture models. J Peripher Nerv Syst 2006; 11: 225-31.

  36. Miltenberger-Miltenyi G, Schwarzbraun T, Löscher W, Wanschitz J, Windpassinger C, Duba H, et al. Identification and in silico analysis of 14 novel GJB1, MPZ and PMP22 gene mutations. Eur J Hum Genet 2009; 17: 1154-9.

  37. Murphy SM, Polke J, Manji H, Blake J, Reiniger L, Sweeney M, et al. A novel mutation in the nerve-specific 5’UTR of the GJB1 gene causes X-linked Charcot-Marie-Tooth disease. J Peripher Nerv Syst 2011; 16(1):65-70.

  38. Mandich P, Grandis M, Geroldi A, Acquaviva M, Varese A, Gulli R, et al. Gap junction beta 1 (GJB1) gene mutations in Italian patients with X-linked Charcot-Marie-Tooth disease. J Hum Genet 2008; 53: 529-33.

  39. Engelfried K, Vorgerd M, Hagedorn M, Haas G, Gilles J, Epplen J, et al. Charcot-Marie-Tooth neuropathy type 2A: novel mutations in the mitofusin 2 gene (MFN2). BMC Med Genet 2006; 7: 53.

  40. Dillon R, Brown S, Ling C, Shioda T, Muller W. An EGR2/CITED1 Transcription Factor Complex and the 14-3-3 ä Tumor Suppressor Are Involved in Regulating ErbB2 Expression in a Transgenic-Mouse Model of Human Breast Cancer. Mol Cell Biol 2007; 27: 8648-57.

  41. Rogers T, Chandler D, Angelicheva D, Thomas P, Youl B, Tournev I, et al. Novel Locus for Autosomal Recessive Peripheral Neuropathy in the EGR2 Region on 10q23. Am J Hum Genet 2000; 67: 664-71.

  42. Pareyson D, Marchesi C. Diagnosis, natural histor y, and management of Charcot-Marie-Tooth disease. Lancet Neurol 2009; 8: 654-67.

  43. Pareyson D. Differential diagnosis of Charcot-Marie-Tooth disease. Neurol Sci 2004;25:72-82.

  44. Latour P, Boutrand L, Levy N, Bernard R, Boyer A, Claustrat F, et al. Polymorphic Short Tandem Repeats for Diagnosis of the Charcot-Marie-Tooth IA Duplication. Clin Chem 2001; 47 (5): 829-37.

  45. Bird TD. Charcot-Marie-Tooth hereditary neuropathy overview. In: Pagon RA, Bird TD, 2011, Dolan CR, Stephens K, editors. GeneReviews [Internet]. Seattle (WA). University of Washington, Seattle; 1993-. 1998 Sep 28 [updated 2011 Jan 25].

  46. Schenone A, Nobbio L, Monti Bragadin M, Ursino G, Grandis M. Inherited neuropathies. Curr Treat Options Neurol 2011; 13 (2):160-79.

  47. Zheng H, Qiao C, Wang CH, Li J, Li J, Yuan Z, et al. Efûcient retrograde transport of adeno-associated virus type 8 to spinal cord and dorsal root ganglion after vector delivery in muscle. Hum Gene Ther 2010; 21: 87-97.

  48. Sereda MW, Nave KA. Animal models of Charcot-Marie-Tooth disease Type 1A. Neuromolecular Med 2006; 8 (1-2): 205-16.

  49. Oppenheim RW, Houenou LJ, Johnson JE, Lin LF, Li L, Lo AC, et al. Developing motor neurons rescued from programmed and axotomy-induced cell death by GDNF. Nature 1995;373 (6512):344-6.

  50. Yan Q, Matheson C, López OT. In vivo neurotrophic effects of GDNF on neonatal and adult facial motor neurons. Nature 1995; 373(6512):341-4.

  51. Dequen F, Filali M, Larivière RC, Perrot R, Hisanaga S, Julien JP. Reversal of neuropathy phenotypes in conditional mouse model of Charcot-Marie-Tooth disease type 2E. Hum Mol Genet 2010; 19 (13): 2616-29.

  52. Rangaraju S, Madorsky I, Pileggi JG, Kamal A, Notterpek L. Pharmacological induction of the heat shock response improves myelination in a neuropathic model. Neurobiol Dis 2008; 32(1): 105-15.

  53. Young P, De Jonghe P, Stögbauer F, Butterfass-Bahloul T. Treatment for Charcot-Marie-Tooth Disease. Cochrane Database Syst Rev 2008; (1): CD006052.

  54. Clinical Trials. URL: http://clinicaltrials.gov [11.11.2011].

  55. Reilly MM, Shy ME, Muntoni F, Pareyson D. 168th ENMC International Workshop: Outcome measures and clinical trials in Charcot–Marie–Tooth disease (CMT). Neuromuscular Disord 2010; 839-46.

  56. Pareyson D, Reilly MM, Schenone A, Fabrizi GM, Cavallaro T, Santoro L, et al. Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. Lancet Neurol 2011; 10 (4): 320-8.

  57. Niemann A, Berger P, Suter U. Pathomechanisms of mutant proteins in Charcot-Marie-Tooth disease. Neuromolecular Med 2006; 8: 217-42.




2020     |     www.medigraphic.com